Clinical trials: ACTH
Patient Admitted in Reanimation
Hydrocortisone Use After Etomidate in Intensive Care
the objective of the study is to assess the value of substitution with 200mg/24h of hydrocortisone for 48 hours for patients in intensive care who have received a single injection of etomidate
- Trial name
- NCT00862381
- Testing
- Hydrocortisone
- Where
- 2 sites in France
- Volunteers
- 106 people
- Sponsor
- University Hospital, Grenoble
Stress Disorders, Post-Traumatic
Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder
This study will test the hypothesis of whether an antagonist at the corticotropin releasing factor type 1 (CRF1) receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of post-traumatic stress disorder (PTSD).
- Trial name
- NCT01018992
- Testing
- GSK561679
- Where
- 4 sites in United States
- Volunteers
- 267 people
- Sponsor
- Emory University
IgA Nephropathy, Proteinuria
Acthar on Proteinuria in IgA Nephropathy Patients
IgA nephropathy occurs when IgA-a protein that helps the body fight infections-settles in the kidneys. IgA deposits may cause the kidneys to leak blood and sometimes protein in the urine.
- Trial name
- NCT02382523
- Testing
- Acthar 80 unit injection
- Where
- United States
- Sponsor
- Baylor College of Medicine
Adrenal Gland Hyperfunction, Adrenal Gland Hypofunction
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency
Corticotropin Releasing Hormone (CRH) is a hypothalamic hormone made up of 41 amino acids. Amino acids are proteins that when combined make up different substances, like hormones.
- Conditions
- Adrenal Gland Hyperfunction, Adrenal Gland Hypofunction, Cushing's Syndrome, Healthy
- Trial name
- NCT00001180
- Testing
- Ovine Corticotropin-Releasing Hormone (oCRH)
- Where
- United States
- Volunteers
- 2,250 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Steroid-Resistant Nephrotic Syndrome
ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children
We propose to study the use of purified porcine Acthar Gel (ACTHAR, Mallinckrodt Pharmaceuticals) for treatment of steroid resistance nephrotic syndrome (SRNS) in a prospective pilot study.
- Trial name
- ADRENL (NCT03408405)
- Testing
- Acthar Gel 80 UNT/ML Injectable Solution
- Sponsor
- Rhode Island Hospital
Cushings Disease, Cushing Disease
Safety and Efficacy of LCI699 in Cushing's Disease Patients
This exploratory study is a proof of concept study to determine whether LCI699 can safely reduce the level of urinary free cortisol in patients with Cushing's disease.
- Trial name
- NCT01331239
- Testing
- LCI699
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Primary Aldosteronism, Autonomous Cortisol Secretion
Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion
To evaluate the incidence of adrenal insufficiency after surgery in Primary aldosteronism (PA) patients concurrent with or without autonomous cortisol secretion (ACS).
- Conditions
- Primary Aldosteronism, Autonomous Cortisol Secretion, Adrenal Insufficiency
- Trial name
- NCT06955286
- Testing
- complete ACTH stimulation test the day after surgery and complete ACTH stimulation test 1 or 4 week for patients with Adrenal Insufficiency
- Where
- China
- Volunteers
- 521 people
- Sponsor
- Qifu Li
Major Depressive Disorder
Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?
The primary objective of this project is to determine whether treatment with the SSRI, fluoxetine versus placebo reverses alterations in the central CRF system induced by early life stress experiences (i.e.
- Trial name
- NCT00208897
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Emory University
Brain Edema, Brain Tumor
Tolerability Study of Xerecept® in Pediatric Patients
This study is being conducted to evaluate the safety and tolerability of Xerecept® in children with central nervous system tumors and to identify appropriate doses of Xerecept® to be used in subsequent pediatric clinical trials.
- Trial name
- NCT01369121
- Testing
- XERECEPT
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celtic Pharma Development Services
Osteoporosis, Cortisol Excess
Prevalence of Hidden Hypercortisolism in Osteoporosis
The goals of this observational study are the following: i) to assess the prevalence of hidden hypercortisolism (HidHyCo) in a sample of osteoporotic patients; ii) to compare the clinical characteristics between…
- Trial name
- OSTCOR (NCT05762549)
- Where
- 5 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Istituto Auxologico Italiano
Brain and Central Nervous System Tumors, Metastatic Cancer
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
RATIONALE: Learning about the side effects of stereotactic radiosurgery in patients with brain tumors or other brain disorders may help doctors plan treatment and help patients live more comfortably.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity
- Trial name
- NCT00255671
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
Idiopathic Membranous Nephropathy
Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy
The purpose of this study is to determine whether treatment with long-acting synthetic adrenocorticotropic hormone is in the treatment of patients with idiopathic membranous nephropathy and high for renal failure.
- Trial name
- ACTHiMeN (NCT00694863)
- Testing
- tetracosactide hexacetaat
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Cushing's Syndrome, Ectopic Corticotropin Syndrome
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
The study aim was to investigate the efficacy and safety of Osilodrostat in patients with Cushing's syndrome due to causes other than Cushing's disease in Japan.
- Conditions
- Cushing's Syndrome, Ectopic Corticotropin Syndrome, Adrenal Adenoma, Adrenal Carcinoma
- Trial name
- NCT02468193
- Testing
- Osilodrostat
- Where
- 4 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Multiple Sclerosis
Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS
The primary objective of this study is to determine if monthly pulse doses of a three-day course ACTH (H.P. Acthar®) is more effective at recovering myelin at 12 months, as measured by myelin water fraction (MWF), in new multiple…
- Trial name
- NCT02446886
- Testing
- Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Primary Aldosteronism
Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism
The project is aimed to determine the value of synacthen infusion on the results of adrenal venous sampling in patients examined for primary aldosteronism
- Trial name
- ISIRA (NCT02127840)
- Testing
- Synacthen infusion during adrenal venous sampling
- Where
- Czechia
- Volunteers
- 40 people
- Sponsor
- Charles University, Czech Republic
Relapsing Remitting Multiple Sclerosis
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
- Trial name
- NCT02258217
- Testing
- Acthar
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- OhioHealth
SLE Glomerulonephritis Syndrome, WHO Class V
ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
This is an open-label, randomized, multi-center, Phase IV study of Acthar Gel in patients with biopsy-proven membranous (Class V) lupus nephritis (LN) aimed at providing proof-of-concept data that Acthar is a safe and effective…
- Trial name
- NCT01926054
- Testing
- Acthar gel
- Where
- United States
- Sponsor
- Ohio State University
Hashimoto Disease, Adrenal Insufficiency
Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis
The purpose of this study is to determine whether patients with Hashimoto thyroiditis and impaired well-being may have a partial secondary adrenocortical insufficiency.
- Trial name
- NCT00552487
- Testing
- synacthen
- Where
- Germany
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of Wuerzburg
Sinusitis
The Long-Term Safety of Budesonide for Patients With Chronic Rhinosinusitis
Chronic Rhinosinusitis (CRS) is a common disorder of the nose. The current practice at St Paul's Sinus Centre is to prescribe budesonide via the mucosal atomization device or impregnated saline irrigation.
- Trial name
- NCT03584178
- Testing
- Budesonide via MAD device, Budesonide via intranasals Saline Irrigation
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- St. Paul's Hospital, Canada